TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations

The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo, has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most c...

Descripción completa

Detalles Bibliográficos
Autor principal: Chhabra, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720046/
https://www.ncbi.nlm.nih.gov/pubmed/21218269
http://dx.doi.org/10.1100/tsw.2011.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720046/
https://www.ncbi.nlm.nih.gov/pubmed/21218269
http://dx.doi.org/10.1100/tsw.2011.10

Ejemplares similares